Congress released damning results of an 18-month investigation into the FDA's approval of Biogen's Alzheimer's drug, Aduhelm. The systems that enabled Biogen's actions, however, went largely unscrutinized.
In a social media landscape shaped by hashtags, algorithms, and viral posts, nurse leaders must decide: Will they let the narrative spiral, or can they adapt and join the conversation?
...
